Raymond R. Mattingly

Raymond R. Mattingly serves as Professor and Chair of the Department of Pharmacology & Toxicology at East Carolina University, where he leads research initiatives focused on molecular mechanisms of disease and therapeutic development. His academic leadership spans decades with significant contributions to cancer pharmacology and signal transduction research.

His educational foundation includes:

• B.A. (Hons.) in Natural Sciences/Pharmacology from the University of Cambridge (1987)
• Ph.D. in Pharmacology from the University of Virginia (1993)

Dr. Mattingly's research program investigates small GTPases of the Ras superfamily, particularly their roles in pathological conditions with hyperactivated Ras signaling without direct Ras mutations. His laboratory specializes in Type 1 Neurofibromatosis (NF1) and breast cancer progression, developing advanced 3D in vitro models that bridge the gap between conventional 2D cultures and animal studies. This approach enables more physiologically relevant drug screening for NF1 therapeutics and identifies molecular targets for triple-negative breast cancer and DCIS-to-invasive carcinoma transitions.

Analysis of his 2018-2021 publications reveals consistent focus on tumor microenvironment dynamics, with particular emphasis on lymphatic metastasis mechanisms in triple-negative breast cancer, ERK/MAPK pathway regulation in tumor progression, and computational modeling of proteolytic processes. His work demonstrates how Rap1Gap downregulation and Sprouty4 suppression serve as molecular switches driving invasive transitions.

No scientific awards were documented in the provided materials.

While student advising details and grant funding specifics were not disclosed in the available documentation, his collaborative projects indicate active mentorship within cancer research teams. His laboratory maintains strong partnerships focused on mechanistic drug discovery for neurofibromatosis and breast cancer subtypes.

Dr. Mattingly directs a research team developing innovative 3D culture platforms for plexiform neurofibroma and breast cancer models, with current work emphasizing tumor-lymphatic interactions and spatio-temporal proteolysis imaging. These models facilitate high-throughput drug screening while maintaining physiological relevance, addressing critical limitations in traditional preclinical cancer research.